• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Zoetis Inc.

    6/23/25 4:44:01 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    11-K 1 zoetis202411-ksavingsplan.htm 11-K Document
    Table of Contents

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     

    FORM 11-K

    (Mark One)    
    ☒
    ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2024
    or
     
    ☐
    TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from __________ to __________
    Commission File No: 001-35797
     
    A. Full title of the plan and the address of the plan, if different from that of the issuer named below:
    ZOETIS SAVINGS PLAN
    B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
    Zoetis Inc.
    10 Sylvan Way
    Parsippany, New Jersey 07054

     
     


     

     
     













    Table of Contents
    REQUIRED INFORMATION:
    Items 1 through 3: Not required; see Item 4 below.
    Item 4. Financial Statements and Exhibits.
    a)Report of Independent Registered Public Accounting Firm
    Statements of Net Assets Available for Benefits as of December 31, 2024 and 2023
    Statements of Changes in Net Assets Available for Benefits for the Years Ended December 31, 2024 and 2023
    Notes to Financial Statements
    Supplemental Schedule
    Schedule H, Line 4i – Schedule of Assets (Held at End of Year) as of December 31, 2024
    b)Exhibit 23.1 Consent of Independent Registered Public Accounting Firm







    Table of Contents
    ZOETIS SAVINGS PLAN
    Index
     
    Page
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements:
    Statements of Net Assets Available for Benefits as of December 31, 2024 and 2023
    2
    Statements of Changes in Net Assets Available for Benefits for the Years Ended December 31, 2024 and 2023
    3
    Notes to Financial Statements4
    Supplemental Schedule:
         Schedule H, Line 4i – Schedule of Assets (Held at End of Year) as of December 31, 2024
    9
    Signature10
    Exhibits:
    Exhibit 23.1 Consent of Independent Registered Public Accounting Firm
    11
     




     




    Table of Contents

    Report of Independent Registered Public Accounting Firm

    To the Plan Participants and Plan Administrator
    Zoetis Savings Plan:

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of Zoetis Savings Plan (the Plan) as of December 31, 2024 and 2023, the related statements of changes in net assets available for benefits for the years ended December 31, 2024 and 2023, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the years ended December 31, 2024 and 2023, in conformity with U.S. generally accepted accounting principles.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Accompanying Supplemental Information

    The Schedule H, line 4i – Schedule of Assets (Held at End of Year) as of December 31, 2024 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ KPMG LLP
    We have served as the Plan’s auditor since 2013.
    Baton Rouge, Louisiana
    June 23, 2025

    1

    Table of Contents
    ZOETIS SAVINGS PLAN
    Statements of Net Assets Available for Benefits

    December 31,
    (thousands of dollars)20242023
    Assets:
    Investments at fair value$1,869,752 $1,749,296 
    Receivables:
    Notes receivable from participants14,838 14,215 
    Employee contributions— 3 
    Employer contributions47,578 37,830 
    Total receivables62,416 52,048 
    Net assets available for benefits$1,932,168 $1,801,344 


    See accompanying notes to financial statements.
    2

    Table of Contents
    ZOETIS SAVINGS PLAN
    Statements of Changes in Net Assets Available for Benefits
    December 31,
    (thousands of dollars)20242023
    Investment income:
    Net appreciation in investments$150,121 $268,937 
    Dividend income19,999 11,784 
    Investment income on participant-directed funds3,341 2,365 
    Total investment income173,461 283,086 
    Interest income on notes receivable from participants1,383 1,035 
    Less: Investment management fees(526)(505)
    Net investment income and interest income174,318 283,616 
    Contributions:
    Employer79,510 67,535 
    Participant72,571 68,664 
    Rollovers8,041 10,450 
    Total contributions160,122 146,649 
    Benefits and withdrawals paid to participants(203,616)(124,511)
    Net increase in assets available for benefits130,824 305,754 
    Net assets available for benefits:
    Beginning of period1,801,344 1,495,590 
    End of period$1,932,168 $1,801,344 

    See accompanying notes to financial statements.
    3

    Table of Contents
    Zoetis Savings Plan
    Notes to Financial Statements
    December 31, 2024 and 2023
    1.Plan Description
    The Zoetis Savings Plan (the Plan) is a defined contribution retirement plan. Participation in the Plan is open to eligible employees of Zoetis Inc. (Zoetis, the Plan Sponsor or the Company) or an affiliate which has, with the consent of the Plan Sponsor, adopted the Plan (Participating Employers) and who are included within a group or class designated by the Plan Sponsor as set forth in the Plan document.
    The Plan is subject to certain provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA) and the Internal Revenue Code of 1986, as amended (the Code). The Plan is designed to meet ERISA’s reporting and disclosure and fiduciary responsibility requirements, as well as the minimum standards for participation and vesting.
    The following is a general description of certain provisions of the Plan. Participants should refer to the Plan document for more detailed and complete information.
    Plan Administration
    The Plan is administered by the Zoetis Savings Plan Committee, which was appointed by the Chief Human Resources Officer of Zoetis pursuant to a delegation of authority by the Zoetis Board of Directors. The investment fiduciary function is also governed by the Zoetis Savings Plan Committee, and the Company has retained a consultant to perform investment consulting services for the Plan and qualifies as a party-in-interest. Bank of America is the Plan’s recordkeeper and trustee and is a party-in-interest to the Plan.
    Administrative Costs
    In general, the Plan or the Plan Sponsor and Plan participants both share in the costs and expenses of administering the Plan. All other administrative fees and expenses are paid for by the Plan or the Plan Sponsor.
    Eligibility
    Generally, all U.S.-based full-time employees of the Company, except (1) certain employees who are covered by a collective bargaining agreement and have not negotiated to participate in the Plan, (2) certain employees who are employed by a unit not designated for participation in the Plan, or (3) certain employees who are otherwise eligible for another Company-sponsored savings plan, are eligible to enroll in the Plan on their date of hire.
    Newly eligible participants who do not affirmatively enroll in the Plan within 30 days of hire or transfer into eligible employment are automatically enrolled at a 5% pre-tax contribution rate. Employees may elect to opt-out of the Plan at any time.
    Unless otherwise directed by the plan participants, contributions are invested in the Plan’s default investment fund option, which is generally the Vanguard Target Retirement Fund, based on the participant’s retirement eligibility date.
    Contributions
    Participants may elect to make contributions of up to 30% of eligible compensation on a pre-tax basis and up to 30% of eligible compensation on a Roth 401(k) or after-tax basis. Total contributions may not be greater than 60% of eligible compensation and are subject to certain restrictions under the Code. For all participants, contributions of up to 5% of eligible compensation are matched 100% by the Company. Participant contributions in excess of 5% are not matched.
    The Plan Sponsor may, in its sole discretion, also make a profit-sharing contribution of up to 8% of each participant’s eligible compensation, as defined by the Plan. Participants are eligible to receive a profit-sharing contribution if they are employed on the last day of the Plan year or die, become disabled (while an employee) or terminate employment after attaining age 55 during the Plan year. In March 2025, the Company made a profit-sharing contribution for plan year 2024 in the amount of approximately $39.9 million. In March 2024, the Company made a profit-sharing contribution for plan year 2023 in the amount of approximately $30.2 million.
    Participant Accounts and Vesting
    Each participant's account is credited with the participant's contributions, the Company's matching and profit-sharing contributions, and the participant's respective share of Plan earnings and is charged with the participant's withdrawals and distributions, and the participant's respective share of Plan losses. Participants are immediately vested in the full value of their account (i.e., participant's and Company's matching contributions) other than the profit-sharing contribution.
    4

    Table of Contents
    Zoetis Savings Plan
    Notes to Financial Statements
    December 31, 2024 and 2023
    All participants will vest in the Company’s profit-sharing contribution as follows:                
    Years of ServicePercentage Vested*
    Under 1 year0%
    1 year20%
    2 years40%
    3 years60%
    4 years80%
    5 years100%
    *Special Vesting Rules for Legacy Abaxis Employees: Profit-sharing contributions of legacy Abaxis employees hired prior to June 24, 2019, the Abaxis Plan Merger Date, will be subject to a 4-year vesting schedule while all other participants will be subject to the Zoetis 5-year vesting schedule as described above. Prior service for legacy Abaxis employees will count toward the vesting of profit-sharing account balances.
    Forfeited balances of terminated participants’ nonvested accounts are used to reduce future employer contributions. Forfeitures used to reduce employer contributions were $1.2 million for the years ended December 31, 2024 and 2023. Forfeited nonvested accounts available to reduce future employer contributions totaled $0.6 million at December 31, 2024 and $0.5 million at December 31, 2023.
    Rollovers into Plan
    Participants may elect to roll over one or more account balances from qualified plans.
    Investment Options
    Participants can elect to invest amounts credited to their account in any of the investment funds offered by the Plan and transfer amounts between these funds at any time during the year.
    Each participant in the Plan elects to have his or her contributions invested in any one or combination of investment funds in the Plan.
    Contributions made by participants may be invested into a self-directed brokerage account.
    Notes Receivable from Participants
    Plan participants are permitted to borrow against their account balances. The minimum amount a participant may borrow is $1,000 and the maximum amount is the lesser of 50% of the account balance reduced by any current outstanding loan balance, or $50,000, reduced by the highest outstanding loan balance in the preceding 12 months.
    Under the terms of the Plan, loans must be repaid pursuant to a fixed payment schedule within five years, unless the funds are used to purchase a primary residence or other payment terms that were established in a plan subsequently merged into the Plan. Primary residence loans must be repaid within ten years. However, certain primary residence loans existed prior to June 20, 2013, and may have longer repayment terms as they were processed under the rules of the prior plan. The interest rate on all loans is based on the prime rate plus 2% at date of loan issuance. At December 31, 2024, interest rates on outstanding loans ranged from 3.25% to 10.50% with maturities ranging from 2025 to 2035. At December 31, 2023, interest rates on outstanding loans ranged from 3.25% to 10.50% with maturities ranging from 2024 to 2035.
    Interest paid by the participant is credited to the participant's account. Interest income from notes receivable from participants is recorded by the trustee as earned in the participant funds in the same proportion as the original loan issuance. Repayments may not necessarily be made to the same fund from which the amounts were borrowed. Repayments are credited to the applicable funds based on the participant’s investment elections at the time of repayment.
    In the event of termination, participants will have 90 days to repay the loan before the loan is considered taxable to the participant. An additional 10% penalty tax may also apply.
    5

    Table of Contents
    Zoetis Savings Plan
    Notes to Financial Statements
    December 31, 2024 and 2023
    Benefit Payments
    Upon separation from service, retirement or disability, a participant whose account balance is greater than $1,000 is entitled to receive the full value of the account balance or defer payment to a later date, subject to receiving minimum required distributions starting at age 73 for those who attained age 73 after January 1, 2023. A participant whose account balance is $1,000 or less will receive his or her account balance upon termination. In the event of a participant's death, a spouse beneficiary generally may elect a lump sum payment or defer payment until a later date, but not beyond the year in which the participant would have reached age 73 for those who attained age 73 after January 1, 2023. A non-spouse beneficiary generally may defer payment until December 31 of the year following the date of the participant's death.
    In-Service Withdrawals
    Participants in the Plan may make in-service withdrawals after reaching the age of 59½ or hardship withdrawals from their account balances subject to the provisions of the Plan.
    Plan Termination
    The Plan Sponsor expects to continue the Plan indefinitely, but reserves the right to amend, suspend or discontinue it in whole or in part at any time by action of the Plan Sponsor's Board of Directors or its authorized designee. In the event of termination of the Plan, each participant shall be entitled to the full value of his or her account balance as though he or she had retired as of the date of such termination. No part of the invested assets established pursuant to the Plan will at any time revert to the Company, except as otherwise permitted under ERISA.
    2.    Summary of Significant Accounting Policies
    Basis of Accounting
    The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (U.S. GAAP).
    Use of Estimates
    The preparation of financial statements in conformity with U.S. GAAP requires Plan management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, the reported amounts of increases and decreases to net assets during the reporting period, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.
    Investment Valuation
    The Plan’s investments are stated at fair value. Units of the Zoetis Stock Fund are valued based on the combined quoted market prices of the underlying shares of Zoetis common stock and a cash equivalent component. Shares of registered investment companies and common/collective trust funds are valued at quoted or published market prices which represent the net asset value of shares held by the Plan at year-end. Self-directed brokerage accounts consist primarily of money market funds, common stocks and mutual funds, which are valued at quoted or published market prices, and are considered one general type of investment. See Note 4. Fair Value Measurements for additional information regarding the fair value of the Plan’s investments. There have been no changes in the valuation methodologies used at December 31, 2024 and 2023.
    Notes Receivable from Participants
    Notes receivable from participants are measured at their unpaid principal balance, plus any accrued interest. Delinquent notes receivable are classified as distributions based on the terms of the Plan document.
    Risks and Uncertainties
    Investment securities, including Zoetis common stock, are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in their fair values could occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.
    Investment Transactions
    Purchases and sales of securities are reflected on a trade-date basis. Dividend income is recorded on the ex-dividend date. Interest income is recorded as earned.
    6

    Table of Contents
    Zoetis Savings Plan
    Notes to Financial Statements
    December 31, 2024 and 2023
    Net Appreciation in Investments 
    The Plan presents, in the statements of changes in net assets available for benefits, the net appreciation in the value of its investments which consists of the realized gains and losses and the unrealized gains and losses on those investments. Realized gains and losses on sales of investments represent the difference between the net proceeds and the cost of the investments (average cost if less than the entire investment is sold). Unrealized gains and losses on investments represent the change in the difference between the cost of the investments and their fair value at the end of the year.
    Benefit Payments 
    Benefits are recorded when paid.
    3.    Tax Status
    The Plan uses a prototype non-standardized Plan document, sponsored by the Trustee (prototype sponsor), who received a favorable determination letter from the Internal Revenue Service (IRS), dated June 30, 2020, which states that the prototype Plan document satisfies the applicable provisions of the Internal Revenue Code. The prototype Plan has not been materially modified so that the Company believes they may rely on the prototype sponsor’s determination letter for the prototype Plan. The determination letter provided to the Company by the prototype sponsor indicates that the form of the Plan is acceptable under section 401 of the Internal Revenue Code for use by employers for the benefit of their employees. The Plan has been amended since receiving the determination letter. The Plan administrator believes that the Plan is currently designed and being operated in compliance with the applicable requirements of the Code.
    U.S. GAAP requires the Plan administrator to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2024 and 2023, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.
    4.    Fair Value Measurements
    The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements: Level 1, meaning the use of quoted or published prices for identical instruments in active markets; Level 2, meaning the use of quoted or published prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and Level 3, meaning the use of unobservable inputs. See Note 2. Summary of Significant Accounting Policies: Investment Valuation for information regarding the methods used to determine the fair value of the Plan’s investments.
    Investments measured at fair value are summarized below:
    Investments at Fair Value as of December 31, 2024
    (thousands of dollars)Level 1Level 2Level 3Total
    Zoetis Stock Fund$160,924 $— $— $160,924 
    Mutual funds365,628 — — 365,628 
    Common/collective trust funds1,305,257 — — 1,305,257 
    Money market funds2,539 — — 2,539 
    Self-directed brokerage funds35,404 — — 35,404 
    Total investments at fair value$1,869,752 $— $— $1,869,752 

    7

    Table of Contents
    Zoetis Savings Plan
    Notes to Financial Statements
    December 31, 2024 and 2023
    Investments at Fair Value as of December 31, 2023
    (thousands of dollars)Level 1Level 2Level 3Total
    Zoetis Stock Fund$209,872 $—$—$209,872 
    Mutual funds339,098 ——339,098 
    Common/collective trust funds1,171,894 ——1,171,894 
    Money market funds1,896 ——1,896 
    Self-directed brokerage funds26,536 ——26,536 
    Total investments at fair value$1,749,296 $—$—$1,749,296 
    5.    Related-Party Transactions
    Certain Plan investments held by the Plan at December 31, 2024 and 2023, were units of the T. Rowe Price Stable Value Common Trust Fund and were managed by Bank of America. Bank of America serves as the trustee of the Plan, and therefore, transactions involving these investments are considered party-in-interest transactions.
    The Plan invests in shares of the Company. The Company is the Plan sponsor, and therefore, these transactions qualify as party-in-interest transactions. At December 31, 2024 and 2023, the Plan held Zoetis common stock valued at $160.9 million and $209.9 million, respectively. For the year ended December 31, 2024, the Plan purchased Zoetis common stock with a fair value of approximately $24.8 million and sold Zoetis common stock with a fair value of approximately $37.1 million. For the year ended December 31, 2023, the Plan purchased Zoetis common stock with a fair value of approximately $21.7 million and sold Zoetis common stock with a fair value of approximately $31.7 million.
    At December 31, 2024 and 2023, the Plan had notes receivable from participants of approximately $14.8 million and $14.2 million, respectively. These transactions are considered parties-in-interest transactions.
    The Plan paid certain expenses related to plan operations and investment activity to Bank of America, these transactions are party-in-interest transactions under ERISA and are not material in any period presented.
    6.    Subsequent Events
    In connection with the preparation of the financial statements, the Plan administrator has evaluated subsequent events after December 31, 2024, through June 23, 2025, the date of the financial statement issuance, and concluded that no additional disclosure or recordable transactions were required.

    8

    Table of Contents
    ZOETIS SAVINGS PLAN
    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    DECEMBER 31, 2024
    (thousands of dollars)
    Identity of Issuer, Borrower, Lessor or Similar PartyDescription of investmentRate of InterestMaturity DateNumber of Shares or UnitsCostCurrent Value
    BIF Money FundMoney Market5,340 $2,539 $2,539 
    American Europacific Growth R6Mutual Fund283,429 14,660 15,226 
    Blackrock Mid Cap Grth Eqty IMutual Fund1,206,710 42,096 52,251 
    Dodge & Cox International StMutual Fund1,099,726 46,161 54,876 
    MFS Mass Investors Growth Stock R4Mutual Fund2,882,641 91,374 123,002 
    JP Morgan LGCP GRO R6Mutual Fund378,547 25,342 31,699 
    JP Morgan Core Bond Fund CL R6Mutual Fund3,671,506 41,848 37,156 
    Vanguard Explorer FundMutual Fund481,214 47,379 51,418 
    Self-Directed Brokerage Acct— **35,404 
    Vanguard Target Retirement 2020 TR ICommon/Collective Trust436,146 28,681 32,986 
    Vanguard Target Retirement 2025 TR ICommon/Collective Trust569,410 38,832 45,689 
    Vanguard Target Retirement 2030 TR ICommon/Collective Trust1,405,659 99,021 118,286 
    Vanguard Target Retirement 2035 TR ICommon/Collective Trust1,146,129 84,575 102,452 
    Vanguard Target Retirement 2040 TR ICommon/Collective Trust1,306,954 101,083 125,154 
    Vanguard Target Retirement 2045 TR ICommon/Collective Trust860,633 68,841 85,848 
    Vanguard Target Retirement 2050 TR ICommon/Collective Trust778,001 63,151 79,255 
    Vanguard Target Retirement 2055 TR ICommon/Collective Trust463,126 46,244 57,520 
    Vanguard Target Retirement 2060 TR ICommon/Collective Trust509,022 27,175 33,224 
    Vanguard Target Retirement 2065 TR ICommon/Collective Trust155,870 5,328 6,258 
    Vanguard Target Retirement 2070 TR ICommon/Collective Trust25,669 573 628 
    Vanguard Target Retirement Income TR ICommon/Collective Trust240,005 14,532 16,313 
    Blackrock US Debt Index Fd Class MCommon/Collective Trust1,739,836 20,325 20,894 
    Blackrock Russell 1000 GR CL TCommon/Collective Trust320,739 21,290 34,135 
    Blackrock Russell 1000 VL CL TCommon/Collective Trust317,024 14,861 18,930 
    Blackrock MSCI EAFE Equity Fund MCommon/Collective Trust1,219,072 22,155 25,668 
    Blackrock Mid Capitalization MCommon/Collective Trust1,433,527 43,214 55,066 
    Blackrock Tips Class KCommon/Collective Trust1,055,302 15,927 17,385 
    Blackrock Equity Index Fund Class JCommon/Collective Trust8,498,275 169,552 241,205 
    Blackrock Russell 2000 Fund MCommon/Collective Trust1,106,329 25,359 36,061 
    Columbia TR Div Incm Inst 300Common/Collective Trust487,388 48,389 62,212 
    *
    T. Rowe Price Stable Value Class QCommon/Collective Trust90,087,955 90,088 90,088 
    *
    Zoetis Common Stock FundCommon stock fund3,040,885 78,971 160,924 
    Total assets held for investment purposes1,869,752 
    *
    Notes Receivable from Participants
    Interest rates: 3.25% to 10.50%;
    maturity dates: 2025 to 2035
    — — 14,838 
    TOTAL$1,884,590 
     
    *Party-in-interest
    **Costs not required for participant-directed investments

    See accompanying report of independent registered public accounting firm.
    9

    Table of Contents
    SIGNATURE
    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this Annual Report to be signed on its behalf by the undersigned, hereunto duly authorized.
     
    Zoetis Savings Plan
    (Name of Plan)
    June 23, 2025
    By:/s/ JAMES MATTHEWS
    James Matthews
    Member, Zoetis Savings Plan Committee

    10
    Get the next $ZTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    More analyst ratings

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Announces Pricing of $1.85 Billion of Senior Notes

    Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.400% senior notes due 2025 in the aggregate principal amount of $600 million, and (iii) the remainder for general corporate purposes. The offering is expected to close on August 18, 2025, subject to customary closing conditions. Bar

    8/11/25 6:48:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook

    Reports Revenue of $2.5 Billion, Growing 4%, and Net Income of $718 Million, or $1.61 per Diluted Share, Increasing 15% and 18%, Respectively, on a Reported Basis for Second Quarter 2025 Delivers 8% Organic Operational Growth in Revenue and 10% Organic Operational Growth in Adjusted Net Income for Second Quarter 2025 Reports Adjusted Net Income of $783 Million, or Adjusted Diluted EPS of $1.76, for Second Quarter 2025 Raises Full Year 2025 Revenue Guidance to $9.450 - $9.600 Billion with Organic Operational Revenue Growth of 6.5% to 8.0% Following Strong First-Half Performance Raises Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income to 5.5% to 7.

    8/5/25 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on August 5, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpos

    7/1/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    SEC Filings

    View All

    SEC Form 8-K filed by Zoetis Inc.

    8-K - Zoetis Inc. (0001555280) (Filer)

    8/18/25 11:43:10 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Zoetis Inc.

    424B3 - Zoetis Inc. (0001555280) (Filer)

    8/12/25 5:07:58 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Zoetis Inc.

    FWP - Zoetis Inc. (0001555280) (Subject)

    8/11/25 5:17:42 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Broadhurst Vanessa converted options into 1,412 shares and disposed of $68,606 worth of shares (451 units at $152.12), increasing direct ownership by 52% to 2,818 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    7/28/25 5:14:33 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Vice President Sarbaugh Keith

    4 - Zoetis Inc. (0001555280) (Issuer)

    7/15/25 4:57:28 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Vice President Lagano Roxanne

    4 - Zoetis Inc. (0001555280) (Issuer)

    7/15/25 4:57:15 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoetis downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Zoetis from Outperform to Market Perform and set a new price target of $155.00

    7/17/25 8:01:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by Stifel with a new price target

    Stifel downgraded Zoetis from Buy to Hold and set a new price target of $160.00

    6/18/25 7:45:54 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Zoetis with a new price target

    Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

    12/2/24 7:04:18 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    $ZTS
    Financials

    Live finance-specific insights

    View All

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

    New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu

    11/11/24 9:20:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

    Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand

    4/1/24 4:30:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook

    Reports Revenue of $2.5 Billion, Growing 4%, and Net Income of $718 Million, or $1.61 per Diluted Share, Increasing 15% and 18%, Respectively, on a Reported Basis for Second Quarter 2025 Delivers 8% Organic Operational Growth in Revenue and 10% Organic Operational Growth in Adjusted Net Income for Second Quarter 2025 Reports Adjusted Net Income of $783 Million, or Adjusted Diluted EPS of $1.76, for Second Quarter 2025 Raises Full Year 2025 Revenue Guidance to $9.450 - $9.600 Billion with Organic Operational Revenue Growth of 6.5% to 8.0% Following Strong First-Half Performance Raises Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income to 5.5% to 7.

    8/5/25 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on August 5, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpos

    7/1/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Third Quarter 2025 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, July 18, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The c

    5/21/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care